Caraco Pharmaceutical Laboratories, the US arm of Sun Pharma, is withdrawing two lots of the drug as "stability results found the product did not meet the drug release dissolution specifications," according to information on the US Food and Drug Administration website.
The company is recalling 1,60,105 bottles of Venlafaxine Hydrochloride extended release tablets of 150 mg strength and 91,777 bottles of 37.5 mg strength in the US market. Caraco initiated the nationwide recall on March 20.
According to the US health regulator, the recall falls under Class II, in which the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or the probability of serious adverse health consequences is remote.
When contacted, a Sun Pharma spokesperson declined to comment.
Sun Pharma shares declined 1.07 per cent to Rs 624.70 at the close on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
